Spots Global Cancer Trial Database for entrectinib

Every month we try and update this database with for entrectinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia	NCT05396859	Acute Myeloid L... Recurrent Acute... Refractory Acut...	Decitabine and ... Entrectinib Laboratory Biom...	18 Years -	OHSU Knight Cancer Institute
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma	NCT04589832	Uveal Melanoma	PAC-1 Entrectinib	18 Years -	Hoosier Cancer Research Network
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	NCT02568267	Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum...	Entrectinib	18 Years -	Hoffmann-La Roche
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	NCT04302025	Non-small Cell ...	Alectinib Entrectinib Vemurafenib (En... Cobimetinib (En... Pralsetinib (En... Atezolizumab SBRT Resection Chemotherapy Divarasib	18 Years -	Genentech, Inc.
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients	NCT03330990	Advanced Solid ...	Entrectinib Midazolam Hydro...	18 Years -	Hoffmann-La Roche
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	NCT02587650	ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib	18 Years -	University of California, San Francisco
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.	NCT05770544	Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma	Entrectinib	-	Cancer Research UK
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II	NCT05525858	Solid Tumor Advanced Solid ... Metastatic Canc...	Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib	19 Years -	Seoul National University Bundang Hospital
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	NCT02587650	ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib	18 Years -	University of California, San Francisco
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.	NCT05834348	Non-Small Cell ...	lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib	18 Years - 100 Years	Pfizer
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response	NCT04632992	Advanced Unrese...	Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib	18 Years -	Genentech, Inc.
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	NCT04644315	Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous...	Alectinib	18 Years -	Hoffmann-La Roche
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	NCT04302025	Non-small Cell ...	Alectinib Entrectinib Vemurafenib (En... Cobimetinib (En... Pralsetinib (En... Atezolizumab SBRT Resection Chemotherapy Divarasib	18 Years -	Genentech, Inc.
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	NCT05170204	Non-Small Cell ...	Alectinib Entrectinib Durvalumab	18 Years -	Hoffmann-La Roche
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options	NCT02650401	Solid Tumors CNS Tumors	Entrectinib	0 Years - 18 Years	Hoffmann-La Roche
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	NCT05170204	Non-Small Cell ...	Alectinib Entrectinib Durvalumab	18 Years -	Hoffmann-La Roche
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia	NCT05396859	Acute Myeloid L... Recurrent Acute... Refractory Acut...	Decitabine and ... Entrectinib Laboratory Biom...	18 Years -	OHSU Knight Cancer Institute
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II	NCT05525858	Solid Tumor Advanced Solid ... Metastatic Canc...	Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib	19 Years -	Seoul National University Bundang Hospital
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	NCT04644315	Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous...	Alectinib	18 Years -	Hoffmann-La Roche
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site	NCT03498521	Cancer of Unkno...	Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib	18 Years -	Hoffmann-La Roche
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	NCT04589845	Solid Tumors	Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib	-	Hoffmann-La Roche
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	NCT02587650	ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib	18 Years -	University of California, San Francisco
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy	NCT04591431	Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer	Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib	18 Years -	Fondazione per la Medicina Personalizzata
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	NCT05159245	Advanced Cancer Solid Tumor Haematological ...	Alectinib Cobimetinib Vismodegib Trastuzumab+Per... Entrectinib Atezolizumab Vemurafenib Regorafenib Apalutamide Abemaciclib Selpercatinib Dabrafenib Trametinib Dabrafenib+Tram... Pralsetinib	18 Years - 100 Years	Helsinki University Central Hospital
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response	NCT04632992	Advanced Unrese...	Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib	18 Years -	Genentech, Inc.
SMMART Adaptive Clinical Treatment (ACT) Trial	NCT05238831	Advanced Breast... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Sarcom... Anatomic Stage ... Anatomic Stage ... Recurrent Adult... Recurrent Breas... Recurrent Ovari... Recurrent Prost... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage IV Ovaria... Stage IV Pancre...	Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Biopsy Biospecimen Col... Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase-z... Irinotecan Letrozole Nab-paclitaxel Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Quality-of-Life... Trastuzumab Trastuzumab Emt... Vemurafenib Vinorelbine Vismodegib	18 Years -	OHSU Knight Cancer Institute
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.	NCT05770544	Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma	Entrectinib	-	Cancer Research UK
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	NCT04589845	Solid Tumors	Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib	-	Hoffmann-La Roche
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options	NCT02650401	Solid Tumors CNS Tumors	Entrectinib	0 Years - 18 Years	Hoffmann-La Roche
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions	NCT03066661	Cancers With NT...	Entrectinib	-	Hoffmann-La Roche
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases	NCT04603807	Carcinoma, Non-...	Entrectinib Crizotinib	18 Years -	Hoffmann-La Roche

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world:

Spots Global Cancer Trial Database for entrectinib

Every month we try and update this database with for entrectinib cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for entrectinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.